249 related articles for article (PubMed ID: 32530286)
1. Synthesis and Structure-Activity Relationships of 5'-Aryl-14-alkoxypyridomorphinans: Identification of a μ Opioid Receptor Agonist/δ Opioid Receptor Antagonist Ligand with Systemic Antinociceptive Activity and Diminished Opioid Side Effects.
Vekariya RH; Lei W; Ray A; Saini SK; Zhang S; Molnar G; Barlow D; Karlage KL; Bilsky EJ; Houseknecht KL; Largent-Milnes TM; Streicher JM; Ananthan S
J Med Chem; 2020 Jul; 63(14):7663-7694. PubMed ID: 32530286
[TBL] [Abstract][Full Text] [Related]
2. 14-Alkoxy- and 14-acyloxypyridomorphinans: μ agonist/δ antagonist opioid analgesics with diminished tolerance and dependence side effects.
Ananthan S; Saini SK; Dersch CM; Xu H; McGlinchey N; Giuvelis D; Bilsky EJ; Rothman RB
J Med Chem; 2012 Oct; 55(19):8350-63. PubMed ID: 23016952
[TBL] [Abstract][Full Text] [Related]
3. Synthesis, modeling, and pharmacological evaluation of UMB 425, a mixed μ agonist/δ antagonist opioid analgesic with reduced tolerance liabilities.
Healy JR; Bezawada P; Shim J; Jones JW; Kane MA; MacKerell AD; Coop A; Matsumoto RR
ACS Chem Neurosci; 2013 Sep; 4(9):1256-66. PubMed ID: 23713721
[TBL] [Abstract][Full Text] [Related]
4. Novel ligands for the opioid receptors: synthesis and structure-activity relationships among 5'-aryl and 5'-heteroaryl 17-cyclopropylmethyl-4,5 alpha-epoxypyrido[2',3':6,7]morphinans.
Ananthan S; Khare NK; Saini SK; Davis P; Dersch CM; Porreca F; Rothman RB
Bioorg Med Chem; 2003 Sep; 11(18):4143-54. PubMed ID: 12927876
[TBL] [Abstract][Full Text] [Related]
5. Synthesis, opioid receptor binding, and bioassay of naltrindole analogues substituted in the indolic benzene moiety.
Ananthan S; Johnson CA; Carter RL; Clayton SD; Rice KC; Xu H; Davis P; Porreca F; Rothman RB
J Med Chem; 1998 Jul; 41(15):2872-81. PubMed ID: 9667975
[TBL] [Abstract][Full Text] [Related]
6. Identification of opioid ligands possessing mixed micro agonist/delta antagonist activity among pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone [correction of hydropmorphone].
Ananthan S; Khare NK; Saini SK; Seitz LE; Bartlett JL; Davis P; Dersch CM; Porreca F; Rothman RB; Bilsky EJ
J Med Chem; 2004 Mar; 47(6):1400-12. PubMed ID: 14998329
[TBL] [Abstract][Full Text] [Related]
7. Asymmetric synthesis and in vitro and in vivo activity of tetrahydroquinolines featuring a diverse set of polar substitutions at the 6 position as mixed-efficacy μ opioid receptor/δ opioid receptor ligands.
Bender AM; Griggs NW; Anand JP; Traynor JR; Jutkiewicz EM; Mosberg HI
ACS Chem Neurosci; 2015 Aug; 6(8):1428-35. PubMed ID: 25938166
[TBL] [Abstract][Full Text] [Related]
8. Further Optimization and Evaluation of Bioavailable, Mixed-Efficacy μ-Opioid Receptor (MOR) Agonists/δ-Opioid Receptor (DOR) Antagonists: Balancing MOR and DOR Affinities.
Harland AA; Yeomans L; Griggs NW; Anand JP; Pogozheva ID; Jutkiewicz EM; Traynor JR; Mosberg HI
J Med Chem; 2015 Nov; 58(22):8952-69. PubMed ID: 26524472
[TBL] [Abstract][Full Text] [Related]
9. Pyrrolo- and pyridomorphinans: non-selective opioid antagonists and delta opioid agonists/mu opioid partial agonists.
Kumar V; Clark MJ; Traynor JR; Lewis JW; Husbands SM
Bioorg Med Chem; 2014 Aug; 22(15):4067-72. PubMed ID: 24973818
[TBL] [Abstract][Full Text] [Related]
10. Aromatic-Amine Pendants Produce Highly Potent and Efficacious Mixed Efficacy μ-Opioid Receptor (MOR)/δ-Opioid Receptor (DOR) Peptidomimetics with Enhanced Metabolic Stability.
Henry S; Anand JP; Twarozynski JJ; Brinkel AC; Pogozheva ID; Sears BF; Jutkiewicz EM; Traynor JR; Mosberg HI
J Med Chem; 2020 Feb; 63(4):1671-1683. PubMed ID: 31986033
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and biological evaluation of 6alpha- and 6beta-N-heterocyclic substituted naltrexamine derivatives as mu opioid receptor selective antagonists.
Li G; Aschenbach LC; Chen J; Cassidy MP; Stevens DL; Gabra BH; Selley DE; Dewey WL; Westkaemper RB; Zhang Y
J Med Chem; 2009 Mar; 52(5):1416-27. PubMed ID: 19199782
[TBL] [Abstract][Full Text] [Related]
12. A Novel Mu-Delta Opioid Agonist Demonstrates Enhanced Efficacy With Reduced Tolerance and Dependence in Mouse Neuropathic Pain Models.
Lei W; Vekariya RH; Ananthan S; Streicher JM
J Pain; 2020; 21(1-2):146-160. PubMed ID: 31201990
[TBL] [Abstract][Full Text] [Related]
13. Structural Simplification of a Tetrahydroquinoline-Core Peptidomimetic μ-Opioid Receptor (MOR) Agonist/δ-Opioid Receptor (DOR) Antagonist Produces Improved Metabolic Stability.
Henry SP; Fernandez TJ; Anand JP; Griggs NW; Traynor JR; Mosberg HI
J Med Chem; 2019 Apr; 62(8):4142-4157. PubMed ID: 30924650
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and evaluation of 4-substituted piperidines and piperazines as balanced affinity μ opioid receptor (MOR) agonist/δ opioid receptor (DOR) antagonist ligands.
Bender AM; Clark MJ; Agius MP; Traynor JR; Mosberg HI
Bioorg Med Chem Lett; 2014 Jan; 24(2):548-51. PubMed ID: 24365161
[TBL] [Abstract][Full Text] [Related]
15. In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence.
Wells JL; Bartlett JL; Ananthan S; Bilsky EJ
J Pharmacol Exp Ther; 2001 May; 297(2):597-605. PubMed ID: 11303048
[TBL] [Abstract][Full Text] [Related]
16. Dual Pharmacophores Explored via Structure-Activity Relationship (SAR) Matrix: Insights into Potent, Bifunctional Opioid Ligand Design.
Nastase AF; Anand JP; Bender AM; Montgomery D; Griggs NW; Fernandez TJ; Jutkiewicz EM; Traynor JR; Mosberg HI
J Med Chem; 2019 Apr; 62(8):4193-4203. PubMed ID: 30916966
[TBL] [Abstract][Full Text] [Related]
17. Design, syntheses, and pharmacological characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan analogues as opioid receptor ligands.
Yuan Y; Zaidi SA; Stevens DL; Scoggins KL; Mosier PD; Kellogg GE; Dewey WL; Selley DE; Zhang Y
Bioorg Med Chem; 2015 Apr; 23(8):1701-15. PubMed ID: 25783191
[TBL] [Abstract][Full Text] [Related]
18. In vivo characterization of MMP-2200, a mixed δ/μ opioid agonist, in mice.
Lowery JJ; Raymond TJ; Giuvelis D; Bidlack JM; Polt R; Bilsky EJ
J Pharmacol Exp Ther; 2011 Mar; 336(3):767-78. PubMed ID: 21118955
[TBL] [Abstract][Full Text] [Related]
19. SoRI 9409, a non-peptide opioid mu receptor agonist/delta receptor antagonist, fails to stimulate [35S]-GTP-gamma-S binding at cloned opioid receptors.
Xu H; Lu YF; Rice KC; Ananthan S; Rothman RB
Brain Res Bull; 2001 Jul; 55(4):507-11. PubMed ID: 11543951
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and biological evaluation of 14-alkoxymorphinans. 21. Novel 4-alkoxy and 14-phenylpropoxy derivatives of the mu opioid receptor antagonist cyprodime.
Spetea M; Schüllner F; Moisa RC; Berzetei-Gurske IP; Schraml B; Dörfler C; Aceto MD; Harris LS; Coop A; Schmidhammer H
J Med Chem; 2004 Jun; 47(12):3242-7. PubMed ID: 15163203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]